1. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18:3068–3077. PMID:
11001674.
Article
2. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985; 133:403–407. PMID:
4038749.
Article
3. McCaffrey JA, Dodd PM, Herr H, Vlamis V, Mazumdar M, Higgins G, et al. Nonbladder primary site of transitional cell carcinoma (TCC) does not affect probability of response to M-VAC or survival (abstract 1299). Proc Am Soc Clin Oncol. 1998; 17:337a.
4. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer. 1989; 64:2448–2458. PMID:
2819654.
5. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol. 1989; 142(2 Pt 1):289–292. PMID:
2746745.
Article
6. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997; 15:2564–2569. PMID:
9215826.
Article
7. Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003; 98:1863–1869. PMID:
14584068.
Article
8. Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol. 2002; 20:158–166. PMID:
12196899.
Article
9. Bellmunt J, Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001; 11:517–522. PMID:
11493774.
Article
10. Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol. 2000; 164:53–56. PMID:
10840423.
Article
11. Perry MC, Anderson CM, Donehower RC. Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, Mckenna WG, editors. Chemotherapy. Clinical oncology. 2004. New York: Churchill Livingstone;p. 492–493.
12. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, et al. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2005; 28:195–200. PMID:
15803016.
13. Wilkowski R, Thoma M, Duhmke E, Rau HG, Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2004; 58:768–772. PMID:
14967432.
Article
14. Byrne MJ, Phillips M, Powell A, Cameron F, Joseph D, Spry N, et al. Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer. Intern Med J. 2005; 35:336–342. PMID:
15892762.
Article
15. Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR. Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Can J Urol. 2002; 9:1625–1633. PMID:
12431323.
16. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol. 2002; 3:738–747. PMID:
12473515.
Article
17. Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T. Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. Int J Urol. 2004; 11:456–460. PMID:
15242352.
Article
18. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18:3068–3077. PMID:
11001674.
Article
19. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000; 18:1921–1927. PMID:
10784633.
Article
20. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999; 17:2876–2881. PMID:
10561365.
Article
21. Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, et al. Gemcitabine/cisplatin vs MVAC 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany. Urologe A. 2003; 42:1074–1086. PMID:
14513232.
22. de Wit R, Bellmunt J. Overview of gemcitabine triplets in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003; 45:191–197. PMID:
12604129.
23. Meliani E, Lapini A, Serni S, Corvino C, Carini M. Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evalu ation. Urol Int. 2003; 71:37–40. PMID:
12845258.